Regulus Therapeutics Inc (RGLS)
$1.61
+0.03
(+1.9%)▲
Performance
- $1.59$1.65$1.61
1.24%
Downside
Day's Volatility :3.64%
Upside
2.42%
- $1.08$3.79$1.61
32.92%
Downside
52 Weeks Volatility :71.5%
Upside
57.52%
Returns
| Period | Regulus Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -36.29% | 0.0% |
6 Months | -34.98% | 0.0% |
1 Year | -4.82% | 0.0% |
3 Years | -78.96% | -21.1% |
Highlights
Market Capitalization | 103.4M |
Book Value | $1.5 |
Earnings Per Share (EPS) | -1.2 |
PEG Ratio | -0.04 |
Wall Street Target Price | 10.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.73% |
Return On Equity TTM | -53.55% |
Revenue TTM | 5.0M |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | 27677.800000000003% |
Gross Profit TTM | -18.4M |
EBITDA | -37.2M |
Diluted Eps TTM | -1.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.75 |
EPS Estimate Next Year | -0.99 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.16 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 541.61%
Technicals Summary
Sell
Neutral
Buy
Regulus Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Regulus Therapeutics Inc | -0.63% | -34.98% | -4.82% | -78.96% | -81.41% |
 Regeneron Pharmaceuticals, Inc. | 0.53% | 20.61% | 40.93% | 82.08% | 313.49% |
 Novo Nordisk A/s | 2.31% | 2.37% | 41.89% | 174.22% | 452.16% |
 Alnylam Pharmaceuticals, Inc. | -2.2% | 76.34% | 35.57% | 40.87% | 212.74% |
 Vertex Pharmaceuticals Incorporated | 2.37% | 15.84% | 38.0% | 150.97% | 173.61% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Regulus Therapeutics Inc | NA | NA | -0.04 | -0.75 | -0.54 | -0.32 | NA | 1.5 |
Regeneron Pharmaceuticals, Inc. | 30.21 | 30.21 | 1.55 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 45.38 | 45.38 | 2.06 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Regulus Therapeutics Inc | Buy | $103.4M | -81.41% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $125.3B | 313.49% | 30.21 | 32.04% |
Novo Nordisk A/s | Buy | $576.2B | 452.16% | 45.38 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $33.6B | 212.74% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $123.5B | 173.61% | 32.84 | -4.74% |
Insights on Regulus Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 41.9% return, outperforming this stock by 46.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 174.2% return, outperforming this stock by 253.2%
Institutional Holdings
Federated Hermes Inc
19.63%RA Capital Management, LLC
9.55%Vivo Capital, LLC
7.64%Octagon Capital Advisors LP
6.51%Vanguard Group Inc
6.19%BlackRock Inc
6.06%
Company Information
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Organization | Regulus Therapeutics Inc |
Employees | 31 |
CEO | Mr. Joseph P. Hagan M.B.A. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.61
+1.9%
Keyarch Acquisition Corp
$1.61
+1.9%
Connexa Sports Technologies Inc
$1.61
+1.9%
Us Value Etf
$1.61
+1.9%
First Wave Biopharma Inc
$1.61
+1.9%
Global X Msci Next Emerging
$1.61
+1.9%
Fat Projects Acquisition Corp
$1.61
+1.9%
Capital Link Global Fintech
$1.61
+1.9%
Applied Uv Inc
$1.61
+1.9%